This is a summary of the European public assessment report (EPAR) for Invega. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Invega. For practical information about using Invega, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Invega is indicated for the treatment of schizophrenia in adults and in adolescents 15 years and older. Invega is indicated for the treatment of schizoaffective disorder in adults.
Therapeutic Area (MeSH)
ATC Code
N05AX13
ATC Item
paliperidone
Pharmacotherapeutic Group
Psycholeptics
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| paliperidone | N/A | 帕利哌酮 |
EMA Name
Invega
Medicine Name
Invega
Aliases
N/ANo risk management plan link.
